• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

三阴性乳腺癌免疫检查点阻断剂的治疗潜力：一项为期21年的文献计量分析。

Therapeutic potential of triple-negative breast cancer immune checkpoint blockers: A 21-year bibliometric analysis.

作者信息

Sun Zhongli, Liu Cun, Yao Yan, Gao Chundi, Li Huayao, Wang Longyun, Li Ye, Sun Changgang

机构信息

College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.

Department of Traditional Chinese Medicine, Chongqing Three Gorges Medical College, Chongqing, China.

出版信息

Medicine (Baltimore). 2025 Mar 7;104(10):e41739. doi: 10.1097/MD.0000000000041739.

DOI:10.1097/MD.0000000000041739
PMID:40068043
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11903016/
Abstract

BACKGROUND

Triple-negative breast cancer (TNBC) is an aggressive metastatic subtype of BC that frequently develops chemoresistance. Immune checkpoint blockers (ICB) have led to breakthroughs in TNBC treatment. This study aimed to explore research trends and public interest in ICB interventions for TNBC.

METHODS

We searched the Web of Science Core Collection (WoSCC) database for publications related to ICB for TNBC from 2003 to 2024. VOSviewer, CiteSpace, and R package "bibliometrix" were used to analyze the characteristics of ICB publications in TNBC from a quantitative and qualitative perspective and to visualize the results to comprehensively present the research trends in this field.

RESULTS

After removing duplicates, 2698 publications were included. The New England Journal of Medicine may be the leading and influential in the field of ICB in TNBC according to data on the total number of publications, number of citations, and impact factors. Its article entitled "Atezolizumab and Nab-Paclitaxel in Advanced TNBC" is 1 of the most cited articles. Keyword analysis showed that current research hotspots in this field are tumor microenvironment, complete pathological response, neoadjuvant chemotherapy, and PARP inhibitors. Future research hotspots may include the PD-L1 inhibitor durvalumab and antibody-drug conjugates (ADC).

CONCLUSIONS

This study revealed that ICB therapy for TNBC is a rapidly evolving and high-profile topic. Future research should focus on the optimal selection of different targets for ICB in combination with neoadjuvant chemotherapy, ADC, and poly ADP-ribose polymerase inhibitors to treat TNBC.

摘要

背景

三阴性乳腺癌（TNBC）是一种侵袭性转移性乳腺癌亚型，常出现化疗耐药。免疫检查点阻断剂（ICB）已在TNBC治疗中取得突破。本研究旨在探讨ICB干预TNBC的研究趋势和公众关注度。

方法

我们在科学网核心合集（WoSCC）数据库中检索了2003年至2024年与ICB治疗TNBC相关的出版物。使用VOSviewer、CiteSpace和R包“bibliometrix”从定量和定性角度分析ICB治疗TNBC出版物的特征，并将结果可视化，以全面呈现该领域的研究趋势。

结果

去除重复项后，纳入了2698篇出版物。根据出版物总数、被引次数和影响因子数据，《新英格兰医学杂志》可能是TNBC领域ICB方面的领先且有影响力的期刊。其题为《阿特珠单抗和纳米白蛋白紫杉醇治疗晚期TNBC》的文章是被引次数最多的文章之一。关键词分析表明，该领域当前的研究热点是肿瘤微环境、完全病理缓解、新辅助化疗和PARP抑制剂。未来的研究热点可能包括PD-L1抑制剂度伐利尤单抗和抗体药物偶联物（ADC）。

结论

本研究表明，ICB治疗TNBC是一个快速发展且备受关注的话题。未来的研究应聚焦于ICB不同靶点与新辅助化疗、ADC及聚ADP-核糖聚合酶抑制剂联合治疗TNBC的最佳选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/d053234c1dcf/medi-104-e41739-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/db446cf480ac/medi-104-e41739-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/4171eaeda9ac/medi-104-e41739-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/786a3254db72/medi-104-e41739-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/a57f8a04ded4/medi-104-e41739-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/cbb0c25e9016/medi-104-e41739-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/372309c2875d/medi-104-e41739-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/7ba43685e587/medi-104-e41739-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/d0ea5c9accde/medi-104-e41739-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/e3351708041d/medi-104-e41739-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/d053234c1dcf/medi-104-e41739-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/db446cf480ac/medi-104-e41739-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/4171eaeda9ac/medi-104-e41739-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/786a3254db72/medi-104-e41739-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/a57f8a04ded4/medi-104-e41739-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/cbb0c25e9016/medi-104-e41739-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/372309c2875d/medi-104-e41739-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/7ba43685e587/medi-104-e41739-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/d0ea5c9accde/medi-104-e41739-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/e3351708041d/medi-104-e41739-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4087/11903016/d053234c1dcf/medi-104-e41739-g010.jpg

相似文献

1
Therapeutic potential of triple-negative breast cancer immune checkpoint blockers: A 21-year bibliometric analysis.三阴性乳腺癌免疫检查点阻断剂的治疗潜力：一项为期21年的文献计量分析。
Medicine (Baltimore). 2025 Mar 7;104(10):e41739. doi: 10.1097/MD.0000000000041739.
2
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.三阴性乳腺癌免疫检查点阻断反应的生物标志物。
Curr Treat Options Oncol. 2021 Mar 20;22(5):38. doi: 10.1007/s11864-021-00833-4.
3
Fundamental knowledge and research regarding the role of immunity in triple-negative breast cancer from 2014-2024: A bibliometric analysis.2014年至2024年关于免疫在三阴性乳腺癌中作用的基础知识与研究：一项文献计量分析
Hum Vaccin Immunother. 2025 Dec;21(1):2483022. doi: 10.1080/21645515.2025.2483022. Epub 2025 Mar 26.
4
Insights into the historical trajectory and research trends of immune checkpoint blockade in colorectal cancer: visualization and bibliometric analysis.免疫检查点阻断在结直肠癌中的历史轨迹和研究趋势的洞察：可视化和文献计量分析。
Front Immunol. 2024 Oct 31;15:1478773. doi: 10.3389/fimmu.2024.1478773. eCollection 2024.
5
Global research trends and prospects related to tumor microenvironment within Triple Negative Breast Cancer: a bibliometric analysis.全球三阴性乳腺癌肿瘤微环境相关研究趋势和前景：文献计量分析。
Front Immunol. 2023 Dec 4;14:1261290. doi: 10.3389/fimmu.2023.1261290. eCollection 2023.
6
Research hotspots and frontiers of neoadjuvant therapy in triple-negative breast cancer: a bibliometric analysis of publications between 2002 and 2023.三阴性乳腺癌新辅助治疗的研究热点和前沿：2002 年至 2023 年文献的计量学分析。
Int J Surg. 2024 Aug 1;110(8):4976-4992. doi: 10.1097/JS9.0000000000001586.
7
The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments.乳腺癌中的抗癌免疫反应：当前和新兴的生物标志物和治疗方法。
Trends Cancer. 2024 Jun;10(6):490-506. doi: 10.1016/j.trecan.2024.02.008. Epub 2024 Mar 22.
8
Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment.依维莫司联合免疫检查点抑制剂治疗和化疗用于一线转移性三阴性乳腺癌可触发肿瘤微环境中巨噬细胞的重编程、免疫激活和细胞外基质重构。
J Immunother Cancer. 2024 Aug 30;12(8):e009160. doi: 10.1136/jitc-2024-009160.
9
Mapping Intellectual Structures and Research Hotspots of Triple Negative Breast Cancer: A Bibliometric Analysis.三阴性乳腺癌的知识结构与研究热点图谱：一项文献计量分析
Front Oncol. 2022 Jan 3;11:689553. doi: 10.3389/fonc.2021.689553. eCollection 2021.
10
Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer.不同的细胞机制是三阴性乳腺癌化疗与程序性死亡受体1配体（PD-L1）阻断联合治疗的基础。
Cancer Cell. 2025 Mar 10;43(3):446-463.e7. doi: 10.1016/j.ccell.2025.01.007. Epub 2025 Feb 6.

本文引用的文献

1
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.一项新辅助阿替利珠单抗联合白蛋白紫杉醇治疗多柔比星耐药早期三阴性乳腺癌的 II 期研究。
Breast Cancer Res Treat. 2023 Jun;199(3):457-469. doi: 10.1007/s10549-023-06929-9. Epub 2023 Apr 15.
2
Top advances of the year: Breast cancer.年度重大进展：乳腺癌。
Cancer. 2023 Jun 15;129(12):1791-1794. doi: 10.1002/cncr.34752. Epub 2023 Apr 4.
3
ROS-responsive Galactosylated-nanoparticles with Doxorubicin Entrapment for Triple Negative Breast Cancer Therapy.
载阿霉素的 ROS 响应性半乳糖化纳米粒子用于三阴性乳腺癌治疗。
Int J Nanomedicine. 2023 Mar 22;18:1381-1397. doi: 10.2147/IJN.S396087. eCollection 2023.
4
Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer.早期三阴性乳腺癌中靶向PD-1/PD-L1的免疫疗法
J Pers Med. 2023 Mar 15;13(3):526. doi: 10.3390/jpm13030526.
5
Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial.regorafenib、ipilimumab 和 nivolumab 用于微卫星稳定型结直肠癌患者，以及既往化疗后疾病进展：一项 1 期非随机临床试验。
JAMA Oncol. 2023 May 1;9(5):627-634. doi: 10.1001/jamaoncol.2022.7845.
6
Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041).帕博利珠单抗联合白蛋白结合型紫杉醇治疗早期三阴性乳腺癌患者——一项单臂II期试验（NeoImmunoboost，AGO-B-041）
Eur J Cancer. 2023 May;184:1-9. doi: 10.1016/j.ejca.2023.01.001. Epub 2023 Jan 9.
7
Cancer statistics, 2023.癌症统计数据，2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
8
Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer.克服三阴性乳腺癌中PD-1/PD-L1阻断抗性的机制与策略
Cancers (Basel). 2022 Dec 23;15(1):104. doi: 10.3390/cancers15010104.
9
Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.新兴策略：PARP抑制剂与免疫检查点阻断剂联合用于BRCA1和BRCA2突变相关及三阴性乳腺癌
Breast Cancer Res Treat. 2023 Jan;197(1):51-56. doi: 10.1007/s10549-022-06780-4. Epub 2022 Nov 1.
10
A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs.一个世纪以来对迷幻剂的研究：对致幻剂、触觉增强剂、宗教致幻剂和解离性药物的趋势与知识图谱的科学计量分析
Eur Neuropsychopharmacol. 2022 Nov;64:44-60. doi: 10.1016/j.euroneuro.2022.09.004. Epub 2022 Sep 30.